Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PG-102 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity | COMBINATION_PRODUCT | RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity. |
| PG-102 | DRUG | PG-102 is a drug for the treatment of obesity. |
| Placebo | OTHER | The placebo is the RaniPill with saline instead of a drug. |
Top 20 of 32 competitors
PG-102 is an investigational small molecule being developed for the treatment of obesity. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in an early phase trial to evaluate its safety and tolerability in patients with obesity.
PG-102 targets the GLP-1 and GLP-2 receptors. These receptors are involved in metabolic regulation, and their activation is being explored as a therapeutic approach for obesity. The drug is designed to modulate these receptors to potentially influence appetite and energy balance.
PG-102 is being developed by Rani Therapeutics Holdings, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol RANI. The company is conducting clinical research on this drug candidate for the treatment of obesity.
PG-102 is in Phase 1 clinical development. It is an investigational drug that has not yet received regulatory approval. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and pharmacokinetics in participants with obesity.
PG-102 is being evaluated in a Phase 1 clinical trial registered as NCT06891287, titled 'An Early Phase Study of RT-114'. This trial is not yet recruiting and plans to enroll approximately 60 participants with obesity. The study is uncontrolled and does not use randomization or blinding.